Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial-Reference-Cited by-同舟云学术

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

Published:2000-08 Issue:9230 Volume:356 Page:615-620
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Rouleau Jean L,Pfeffer Marc A,Stewart Duncan J,Isaac Debra,Sestier Francois,Kerut Edmund K,Porter Charles B,Proulx Guy,Qian Chunlin,Block Alan J

Publisher

Elsevier BV

Subject

General Medicine

Reference22 articles.

1. The neurohumoral hypothesis and the treatment of heart failure;Rouleau;Can J Cardiol,1996

2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure;N Engl J Med,1991

3. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial;Lancet,1999

4. Angiotensin-converting enzyme inhibition improves cardiac function;Gohlke;Hypertension,1994

5. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors;Remme;Drugs,1997

Cited by 361 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New therapeutic targets in hypertension;Medicina Clínica (English Edition);2024-09

2. Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction;Pharmacological Research;2024-06

3. Nuevas dianas terapéuticas en hipertensión;Medicina Clínica;2024-06

4. Role of angiotensin receptor-neprilysin inhibitor in diabetic complications;World Journal of Diabetes;2024-05-15

5. ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial;Circulation;2024-01-02